164014-94-2

Basic information

• Product Name: 2-METHOXY-6-(TRIBUTYLSTANNYL)PYRIDINE
• Synonyms: 2-METHOXY-6-(TRIBUTYLSTANNYL)PYRIDINE;(6-Methoxypyridin-2-yl)tributylstannane;2-(Tributylstannyl)-6-Methoxypyridine;6-Methoxy-2-(tributylstannyl)pyridine
• CAS NO: 164014-94-2
• Molecular Formula: C₁₈H₃₃NOSn
• Molecular Weight: 398.17072
• Product Categories: Stannanes
• Mol File: 164014-94-2.mol

Chemical Properties

• Boiling Point: 309.3-313.3 °C
• Flash Point: >110 °C
• Appearance: /
• Vapor Pressure: 0mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.37±0.19(Predicted)
• CAS DataBase Reference: 2-METHOXY-6-(TRIBUTYLSTANNYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHOXY-6-(TRIBUTYLSTANNYL)PYRIDINE(164014-94-2)
• EPA Substance Registry System: 2-METHOXY-6-(TRIBUTYLSTANNYL)PYRIDINE(164014-94-2)

Safety Data

• Hazard Codes: T,N
• Statements: 21-25-36/38-48/23/25-50/53
• Safety Statements: 36/37/39-45-60-61
• Hazardous Substances Data: 164014-94-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Methoxy-6-(tributylstannyl)pyridine is used as a building block for the synthesis of various organic compounds, particularly in the pharmaceutical and agrochemical industries. Its unique structure allows for easy attachment to other molecules, making it a valuable component in the development of new drugs and agrochemicals.
Used in Functionalization of Aromatic Compounds:
In the field of organic chemistry, 2-methoxy-6-(tributylstannyl)pyridine is employed as a reagent for the functionalization of aromatic compounds. Its ability to form stable organotin intermediates enables the introduction of various functional groups onto aromatic rings, which is crucial for the synthesis of complex organic molecules.
Used in Cross-Coupling Reactions:
2-Methoxy-6-(tributylstannyl)pyridine is utilized in cross-coupling reactions to form carbon-carbon bonds, a fundamental process in organic synthesis. Its tributylstannyl group allows for efficient coupling with various organic halides, leading to the formation of new carbon-carbon bonds and the synthesis of diverse organic compounds.

InChI:InChI=1/C6H6NO.3C4H9.Sn/c1-8-6-4-2-3-5-7-6;3*1-3-4-2;/h2-4H,1H3;3*1,3-4H2,2H3;/rC18H33NOSn/c1-5-8-14-21(15-9-6-2,16-10-7-3)18-13-11-12-17(19-18)20-4/h11-13H,5-10,14-16H2,1-4H3

Upstream product

• 40473-07-2 6-bromo-2-methoxypyridine 
• 1461-22-9 tributyltin chloride 

Downstream Products

• 1111110-54-3 6-(4-(trifluoromethyl)phenyl)pyridin-2(1H)-one 
• 1202026-99-0 6-methoxy-2-{4-(trifluoromethyl)phenyl}pyridine 
• 1360567-77-6 2-methoxy-6-(2-methoxyphenyl)pyridine 
• 296776-83-5 2-methoxy-6-(4'-methoxyphenyl)pyridine 
• 19006-82-7 6-phenyl-2-pyridone 
• 35070-08-7 2-methoxy-6-phenylpyridine 
• 1608482-83-2 4-chloro-6-(4-isopropoxyphenyl)-6'-methoxy-2,2'-bipyridine 
• 1311375-38-8 1-benzyl-5-((tert-butyldimethylsilyloxy)methyl)-3-(6-methoxypyridin-2-yl)-5,6-dihydropyridin-2(1H)-one 
• 474694-48-9 6-[3-(4-fluorophenyl)-1-trityl-1H-4-pyrazolyl]-3-(6-methoxy-pyridin-2-yl)imidazo[1,2-a]pyridine 

Relevant articles and documents

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

ANTIBACTERIAL COMPOSITIONS

Compounds of formula (I) have antibacterial activity: wherein: m is 0 or 1 ; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (-O-), thioether (-S-) or amino (-NR)- link, wherein R is hydrogen, -CN or C1-C3 alkyl; X is -C(=O)NR6-, -S(O)NR6-, -C(=O)O- or -S(=O)O- wherein R6 is hydrogen, optionally substituted C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -Cyc, or -( C1-C3 alkyl)-Cyc wherein Cyc is optionally substituted monocyclic carbocyclic or heterocyclic having 3-7 ring atoms; Z is N or CH, or CF; R2 and R3 are as defined in the description.

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS

The present invention provides a genus of polycyclic pyrimidines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.

POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS

The present invention provides a genus of polycyclic pyridines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.

Polycyclic pyrazines as potassium ion channel modulators

The present invention provides a genus of polycyclic pyrazines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.